Ganfort beats Xalacom

Article

A bimatoprost and timolol fixed combination (Ganfort; Allergan) is more effective at lowering intraocular pressure (IOP) over 12 weeks than latanoprost (Xalacom; Pfizer), according to results presented at the meeting of the European Glaucoma Society (EGS), held June 1–6 in Berlin.

A bimatoprost and timolol fixed combination (Ganfort; Allergan) is more effective at lowering intraocular pressure (IOP) over 12 weeks than latanoprost (Xalacom; Pfizer), according to results presented at the meeting of the European Glaucoma Society (EGS), held June 1–6 in Berlin.

Antonio Martinez of the Instituto Gallego de Oftalmologia, Spain and colleagues conducted a prospective, randomized, evaluator masked, single centre crossover study, in which open angle glaucoma (OAG) patients (n=54; eyes=108) received a once daily evening dose of either Ganfort or Xalacom for 12 weeks, following an initial six week treatment regime of twice daily timolol maleate 0.5%. Patients in the Ganfort arm then received a further 12 weeks of treatment with Xalacom, and patients in the Xalacom arm went on to receive 12 weeks of Ganfort treatment. IOP was measured at baseline, and at weeks six and 12 of each treatment period; mean IOP range across a 12-hour period was also evaluated.

After 12 weeks of treatment, subjects had a mean baseline IOP of 22.0 mmHg; 12 hours post-treatment, patients treated with Ganfort had a mean IOP of 17.7 mmHg whereas patients treated with Xalacom had a mean IOP of 18.5 mmHg. Ganfort subjects showed a mean IOP fluctuation range of 4.8 mmHg; in Xalacom-treated patients, the range was 5.9 mmHg.

Thus the researchers concluded that, whilst both treatments are efficacious, Ganfort is slightly more effective than Xalacom in reducing IOP in OAG subjects.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.